Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)

NCT05443854 | Unknown Phase 3 DMC

• 1 other identifier: APHP180690
• Study Type: interventional
• Target: 340
• Locations: 0 countries
• Sites: N/A

Brief Summary

Sepsis remains the leading cause of ICU admission in neutropenic patients. This condition remains associated with a high morbidity and mortality, with hospital mortality of 60% when vasopressors are required. Full protective isolation (including geographic isolation, technical isolation, high-efficiency air filtration, and digestive decontamination) proved to be efficient in patients with profound and prolonged neutropenia with regard to infection rate. However, these studies are biased and were performed up to 40 years ago. More recent studies, performed in patients with less profound neutropenia, or performed without digestive decontamination or with partial protective isolation led however to negative results. More importantly, isolation has been demonstrated to limit access to patients' room and to be associated with suboptimal monitoring, with increased rate of severe and avoidable adverse events. This may explain the uneven use of protective isolation in hematology ward and expert's suggestion to appraise protective isolation benefits using large well conducted RCT. In neutropenic patients with suspected sepsis, urgent broad antibiotic therapy is mandatory and failure to initiate adequate antibiotic therapy within 1 hour has been associated with a 10 fold increase in adjusted mortality. Current IDSA guidelines recommend using preferentially large anti-pseudomonas beta-lactam therapy. Routine antibiotic combination using aminoglycosides is controversial and not recommended. On one hand, meta-analyses suggested not-only a lack of benefit from this association but also increased rate of renal failure and a trend towards a higher mortality rate with aminoglycosides use. On the other hand, subgroup analysis and low-level evidences studies suggest however a benefit from aminoglycosides in critically-ill patients, patients with severe sepsis, or those with documented gram negative infection. Along this line, both the recent Cochran systematic review and the recent French guidelines focusing on neutropenia management in critically-ill patients advocated additional trials in this field focusing in the sickest patients. The current study aims to assess benefits of protective isolation and systematic use of aminoglycosides combination antibiotic therapy in critically-ill patients with cancer-related neutropenia and sepsis or septic shock. To do so, the investigators intend to perform a 2x2 factorial design randomized pragmatic trial comparing on one hand benefits of protective isolation (versus no protective isolation) and in the other hand benefits of systematic aminoglycosides antibiotics combination (versus no systematic combination).

Conditions

Sepsis; Septic Shock; Hematologic Malignancy; Tumor; Allogeneic Stem Cell Transplantation

Outcome Measures

Primary Outcomes (1)

• Mortality

  Overall death

  at day 90

Secondary Outcomes (21)

• Mortality

  at Day-28

• Hospital mortality

  at hospital discharge within 3 months

• Incidence of acute kidney injury

  within 3 months

• Severity of acute kidney injury

  within 3 months

• Duration of acute kidney injury

  within 3 months

Study Arms (4)

Aminoglycosides intervention

EXPERIMENTAL

Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered. Recommended duration will be of three days or until microbiological documentation.

Drug: Aminoglycosides intervention

Lack of protective isolation intervention

EXPERIMENTAL

Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained.

Behavioral: Lack of protective isolation intervention

No systematic aminoglycosides intervention

OTHER

Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines - standard arm

Other: No systematic aminoglycosides intervention - standard arm

Protective isolation intervention

OTHER

Protective isolation will be provided systematically as currently practiced in participating centers - standard arm

Other: Protective isolation intervention - standard arm

Interventions

Aminoglycosides intervention DRUG

Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\]. Systematic aminoglycoside therapy using Amikacin at a dose of 25 to 30 mg/Kg per dose, at a rate of a maximum of 1 infusion per day will be delivered. Recommended duration will be of three days or until microbiological documentation.

Aminoglycosides intervention

Lack of protective isolation intervention BEHAVIORAL

Protective isolation will be avoided until ICU discharge is deemed possible. Specific measures regarding nutrition (including avoidance of food consider at risk of fungal contamination) and water protection will be maintained. Extended universal hygiene measures will be maintained and use of mask will be advocated during viral epidemic periods. A high degree of compliance as regard to antifungal prophylaxis guidelines and local standard hygiene procedures will be advocated

Lack of protective isolation intervention

No systematic aminoglycosides intervention - standard arm OTHER

Antibiotic therapy and prophylaxis will be in line with more recent IDSA and ESCMID guidelines \[3, 28, 50\]. No systematic aminoglycoside therapy will be provided except in presence of predefined specific organ infection (such intra-vascular infection such endocarditis for example) or drug-resistant infection requiring aminoglycosides.

No systematic aminoglycosides intervention

Protective isolation intervention - standard arm OTHER

Protective isolation will be provided systematically as currently practiced in participating centers. Modality will be in line with recent SRLF guidelines, we will recommend for the patients to receive an isolation the maximal available isolation with the aim to provide: 1. High-efficiency air filtration \[filtration of 99.7% of particles greater than or equal to 0.3 µm; International Organization for Standardization (ISO) class 5 or better\] 2. Geographical isolation in an individual room 3. Technical isolation, including a face mask and a cap. This approach of isolation will however be pragmatic on the basis of the "best available" level of isolation in line with recommendation, while not delaying ICU admission and patients' care

Protective isolation intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years
• Sepsis or septic shock as defined by SEPSIS3 definition
• Underlying tumor, allogeneic stem cell transplantation or hematological malignancy
• Neutropenia (defined by either absolute neutrophil count \<500/mm3 or leucocytes \<1000/mm3) related to an underlying malignancy or its treatment
• Informed or deferred consent

You may not qualify if:

• Pregnancy and breastfeeding
• Moribund patients (death expected within 48 hours by attending physician)
• Previous participation to this study
• No affiliation to social security
• Patients under legal protection according to French Law
• Patient having received more than 1 injection of aminoglycosides in the 3 days preceding ICU admission
• Contraindication to aminoglycosides as mentioned in SpC section 4.3:
• Hypersensitivity to amikacin, to other antibiotics from the aminoglycoside family, or to any excipient from the amikacin used.
• Patients with documented allergy to aminoglycosides
• Myasthenia gravis

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Sepsis; Shock, Septic; Hematologic Neoplasms; Neoplasms

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Shock; Neoplasms by Site; Hematologic Diseases; Hemic and Lymphatic Diseases

Central Study Contacts

Michael Darmon

CONTACT

01 42 49 94 19; michael.darmon@aphp.fr

Matthieu Resche-Rigon

CONTACT

+33142499742; matthieu.resche-rigon@univ-paris-diderot.fr

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 17, 2022
• First Posted: July 5, 2022
• Study Start: September 1, 2022
• Primary Completion: June 1, 2024
• Study Completion: June 1, 2024
• Last Updated: July 5, 2022

Record last verified: 2022-06